European regulators have backed a new Humira biosimilar for approval, setting up a four-way race for the blockbuster’s market share later this year between Amgen, Boehringer Ingelheim, Sams
Bristol-Myers Squibb is hoping to revive its Opdivo cancer immunotherapy by combining it with an experimental agent from Nektar Therapeutics. But new early stage data from the cocktail pres
Pfizer has been steadily building a franchise around its inflammatory diseases pill, Xeljanz (tofacitinib) over the last few years, and it could add another use after US experts recommended
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.